MGI helps fight COVID-19 pandemic in Laos with innovative container lab with support from LSEA
PAKSE, Laos, March 17, 2022 /PRNewswire/ — MGI Tech Co., Ltd. (MGI), a world leader and innovator in the field of life sciences, developed the Champa LSEA laboratory, the first 3rd party detection center in Laoswith support from the Belt and Road Life Science Economy Alliance (LSEA) and Sithandone Joint Development Co., Ltd. (STD) to help Laos increase its mass testing capacity for Covid-19 and prepare for the gradual reopening of its borders in 2022. As its name suggests, the innovative container laboratory was delivered to the province of Champassak on the 17th of March and is based at Champasak Provincial Hospital, STD’s co-partner in the 11 million dollar project.
As part of the Green Zone Travel Plan program, the Lao government has authorized the partial reopening of its borders to welcome visitors back and revive the travel and tourism sector since January 1stbut as the country faces the continued community spread of Covid-19, the need has never been greater to improve its prevention and control systems.
Built in a 12-meter-long shipping container and designed to meet the demands of large-scale testing, the Champa LSEA laboratory is equipped with MGI’s automation systems allowing laboratory technicians to process up to 3,000 samples per day, and up to 30,000 samples per day if 10 samples are mixed in one tube for batch testing, greatly increasing Laos’ Efficiency and capacity of nucleic acid testing.
The container lab helps simplify laborious and time-consuming procedures usually associated with diagnostic testing, as it comes with two high-level automation systems, namely MGISP-960 and MGISTP-7000 for preparation and transfer of samples respectively, decreasing the need for labor and manual labor while shortening the time to get test results and dramatically streamlining the overall workflow.
Comes complete with extraction reagents, consumables and protective materials, the Biosafety Level 2 lab is further enhanced with state-of-the-art ventilation systems for air exchange, pressure control and sterilization and accommodates three main functional areas: a reagent preparation room, a sample preparation room and an amplification room.
With the innovative and best-in-class approach, the container lab has been designed to be easily transported and quickly deployed in stadiums and sports fields, community and district hospitals, health departments or wherever it may be. is appropriate in emergency situations where mass testing is needed, reducing both sample transport time and travel time for local patients who need to get PCR tested quickly and leave. Additionally, the lab can also serve as a viral mutation monitoring station, making it a versatile instrument in these unprecedented times for pandemic control.
“As a responsible global corporate citizen, MGI’s impact is not only felt in Laosbut also in the South East Asia region and around the world. Since the start of the pandemic, MGI has been instrumental in the fight against Covid-19 by enabling communities and governments to scale up their testing capacity and increase their testing efficiency, while ensuring an environment of safer work for frontline health workers,” says Dr. Roy Tan, Managing Director of MGI Asia-Pacific. As the pandemic strained public health systems in most parts of the world, MGI sought to respond by providing automation systems to over 70 countries to date, including Singapore, Thailand, Malaysia, Saudi Arabia and the United Arab Emirates.
“The Champa LSEA laboratory initiated by Champasak Provincial Hospital and STD will benefit the province of Champasak and surrounding regions in the prevention and control of Covid-19. The advanced equipped laboratory systems provided by MGI will also help minimize the required manpower, and will thus aim to improve the Covid-19-19 testing efficiency and capacity,” said Dr. Khamsing Keothongku, Director of Champasak Provincial Hospital.
Beyond the Covid-19 pandemic, the Champa LSEA laboratory has the potential to become a long-term public health infrastructure for Laos and will continue to bring value to local communities. Using MGI*’s high-throughput sequencing technology, the container lab can help in the prevention and control of other local infectious diseases such as malaria, dengue, tuberculosis, etc. or early detection of birth defects, tumors and other potential diseases. health problems in individuals.
Approved by the Ministry of Health, the Champa LSEA Laboratory is the fruit of the long-standing alliance between China and Laos. By fighting the Covid-19 pandemic together, the two nations stand ready to build a community of shared destiny and prosperity.
MGI Tech Co., Ltd. (MGI), a subsidiary of global genomics leader BGI Group, is committed to creating foundational tools and technologies to lead life sciences through intelligent innovation. Based on its proprietary technology, MGI focuses on the research and development, production and sales of sequencing instruments*, reagents* and related products to support life science research, agriculture , precision medicine and healthcare. MGI’s mission is to develop and promote advanced life science tools for future healthcare. From December 2020, MGI operates in more than 70 countries and regions, serves more than 1,000 international users, and employs more than 1,700 professionals worldwide, 33% of whom are R&D personnel. For more information, visit the MGI website or contact us at TwitterLinkedIn or YouTube.
*Standard MPS and CoolMPS sequencing reagents, and sequencers for use with these reagents, are not available in Germany, United States, SpainUK, hong kong, Sweden, Belgiumand Italy.
Life Sciences Economy Alliance (LSEA) is a unique cross-industry alliance committed to the development of life sciences and technological innovation and the promotion of international cooperation and development of the life sciences industry. The mission of the Alliance is to inspire the life science technology community and create a better world through various platforms and programs. The Champa LSEA laboratory in Laosbuilt by the members of the LSEA, would be an example and would significantly improve Laos’ Precision medicine capabilities. Meanwhile, LSEA also provides a standardized laboratory accreditation system and well-trained operators to ensure the efficiency and quality of nucleic acid testing. LSEA will continue to build a community of human destiny with our members along the “Belt and Road” regions through various forms of exchanges and cooperation.
The new four thousand islands area in the province of Champasak is one of the largest foreign investment projects in Laos and aims to create a green, modern and environmentally friendly city. The promoter, Sithandone Joint Development Co., Ltd. (STD) intends to build a city that includes resorts and recreational facilities and will attract people from all over the world. The development will include an Asian Exhibition and Convention Center and an Agricultural Research Center, as well as processing plants, other buildings and tourism-related services. STD plans to invest more than 9 billion US dollarsaiming to attract 2.3 million visitors per year by 2030 and 15 million visitors per year by 2050. The project site is located in Khong District and the Mekong Islands in the southernmost part of Laos and covers an area of over 9,846 hectares.